Toenail Onychomycosis with or without Diabetes in Canada: Patient Treatment Preferences and Health State Utilities

References

• Gupta AK, Gupta G, Jain HC, et al. The prevalence of unsuspected onychomycosis and its causative organisms in a multicentre Canadian sample of 30 000 patients visiting physicians’ offices. J Eur Acad Dermatol Venereol. 2016;30(9):1567–1572. doi:10.1111/jdv.13677
   PubMed Web of Science ®Google Scholar
• Gupta AK, Versteeg SG, Shear NH. Onychomycosis in the 21st century: an update on diagnosis, epidemiology, and treatment. J Cutan Med Surg. 2017;21(6):525–539. doi:10.1177/1203475417716362
   PubMed Web of Science ®Google Scholar
• Christenson JK, Peterson GM, Naunton M, et al. Challenges and opportunities in the management of onychomycosis. J Fungi. 2018;4(3):87. doi:10.3390/jof4030087
   Web of Science ®Google Scholar
• Elewski BE, Tosti A. Risk factors and comorbidities for onychomycosis: implications for treatment with topical therapy. J Clin Aesthet Dermatol. 2015;8(11):38–42.
   PubMedGoogle Scholar
• Lipner SR, Scher RK. Onychomycosis: clinical overview and diagnosis. J Am Acad Dermatol. 2019;80(4):835–851.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Stec N, Summerbell RC, et al. Onychomycosis: a review. J Eur Acad Dermatol Venereol. 2020;34(9):1972–1990.
   PubMed Web of Science ®Google Scholar
• Rosen T, Friedlander SF, Kircik L, et al. Onychomycosis: epidemiology, diagnosis, and treatment in a changing landscape. J Drugs Dermatol. 2015;14(3):223–233.
   PubMed Web of Science ®Google Scholar
• Baran R. The nail in the elderly. Clin Dermatol. 2011;29(1):54–60. doi:10.1016/j.clindermatol.2010.07.008
   PubMed Web of Science ®Google Scholar
• Winston JA, Miller JL. Treatment of onychomycosis in diabetic patients. Clin Diabetes. 2006;24(4):160–166. doi:10.2337/diaclin.24.4.160
   Google Scholar
• Akkus G, Evran M, Gungor D, Karakas M, Sert M, Tetiker T. Tinea pedis and onychomycosis frequency in diabetes mellitus patients and diabetic foot ulcers. A cross sectional - observational study. Pak J Med Sci. 2016;32(4):891–895. doi:10.12669/pjms.324.10027
   PubMed Web of Science ®Google Scholar
• Rossaneis MA, Haddad MD, Mantovani MF, Marcon SS, Pissinati PS. Foot ulceration in patients with diabetes: a risk analysis. Br J Nurs. 2017;26(6):S6–S14. doi:10.12968/bjon.2017.26.6.S6
   PubMedGoogle Scholar
• Papini M, Cicoletti M, Fabrizi V, Landucci P. Skin and nail mycoses in patients with diabetic foot. Giornale Ital Di Dermatol E Venereol. 2013;148(6):603–608.
   PubMed Web of Science ®Google Scholar
• Foley K, Gupta AK, Versteeg S, Mays R, Villanueva E, John D. Topical and device-based treatments for fungal infections of the toenails. Cochrane Database Syst Rev. 2020;1(1):Cd012093. doi:10.1002/14651858.CD012093.pub2
   PubMedGoogle Scholar
• Fukunaga A, Washio K, Ogura K, et al. Onychomycosis as a warning sign for peripheral arterial disease. Acta Dermato Venereol. 2013;93(6):747–748. doi:10.2340/00015555-1576
   PubMed Web of Science ®Google Scholar
• Ozkan F, Ozturk P, Ozyurt K, et al. Frequency of peripheral arterial disease and venous insufficiency in toenail onychomycosis. J Dermatol. 2013;40(2):107–110. doi:10.1111/1346-8138.12020
   PubMed Web of Science ®Google Scholar
• Gupta AK, Foley KA, Mays RR, Shear NH, Piguet V. Monotherapy for toenail onychomycosis: a systematic review and network meta-analysis. Br J Dermatol. 2020;182(2):287–299. doi:10.1111/bjd.18155
   PubMed Web of Science ®Google Scholar
• Yan J, Wang X, Chen S. Systematic review of severe acute liver injury caused by terbinafine. Int J Clin Pharm. 2014;36(4):679–683. doi:10.1007/s11096-014-9969-y
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Targhotra M, Kumar B, Sahoo PK, Chauhan MK. Treatment and management strategies of onychomycosis. Journal de mycologie medicale. 2020;30(2):100949. doi:10.1016/j.mycmed.2020.100949
   PubMed Web of Science ®Google Scholar
• Mayser P, Freund V, Budihardja D. Toenail onychomycosis in diabetic patients: issues and management. Am J Clin Dermatol. 2009;10(4):211–220. doi:10.2165/00128071-200910040-00001
   PubMed Web of Science ®Google Scholar
• Ameen M, Lear JT, Madan V, Mohd Mustapa MF, Richardson M. British Association of Dermatologists’ guidelines for the management of onychomycosis 2014. Br J Dermatol. 2014;171(5):937–958. doi:10.1111/bjd.13358
   PubMed Web of Science ®Google Scholar
• Torrance GW, Furlong W, Feeny D, Boyle M. Multi-attribute preference functions. Health Utilities Index. Pharmacoeconomics. 1995;7(6):503–520. doi:10.2165/00019053-199507060-00005
   PubMed Web of Science ®Google Scholar
• Tolley KP. What are Health Utilities? Hayward Medical Communications; 2009.
   Google Scholar
• Chen SC, Bayoumi AM, Soon SL, et al. A catalog of dermatology utilities: a measure of the burden of skin diseases. J Investig Dermatol Symp Proc. 2004;9(2):160–168. doi:10.1046/j.1087-0024.2003.09112.x
   PubMedGoogle Scholar
• World Medical Association. WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects; 2022. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/. Accessed February 14, 2024.
   Google Scholar
• Orme B. Sample Size Issues for Conjoint Analysis Studies. Sequim: Sawtooth Software Technical Paper; 1998.
   Google Scholar
• Hahn GHS. A catalog and computer program for the design and analysis of orthogonal symmetric and asymmetric fractional factorial experiments; 1966.
   Google Scholar
• Reed Johnson F, Lancsar E, Marshall D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. Value Health. 2013;16(1):3–13. doi:10.1016/j.jval.2012.08.2223
   PubMed Web of Science ®Google Scholar
• Hauber AB, Gonzalez JM, Groothuis-Oudshoorn CG, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value Health. 2016;19(4):300–315. doi:10.1016/j.jval.2016.04.004
   PubMed Web of Science ®Google Scholar
• R Core Team. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2022. Available from: https://www.R-project.org/. Accessed February 14, 2024.
   Google Scholar
• Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes. 2003;1(1):54. doi:10.1186/1477-7525-1-54
   PubMedGoogle Scholar
• Cathcart S, Cantrell W, Elewski B. Onychomycosis and diabetes. J Eur Acad Dermatol Venereol. 2009;23(10):1119–1122. doi:10.1111/j.1468-3083.2009.03225.x
   PubMed Web of Science ®Google Scholar
• Guertin JR, Feeny D, Tarride JE. Age- and sex-specific Canadian utility norms, based on the 2013–2014 Canadian community health survey. CMAJ. 2018;190(6):E155–E161. doi:10.1503/cmaj.170317
   PubMed Web of Science ®Google Scholar
• Gupta AK, Ryder JE, Skinner AR. Treatment of onychomycosis: pros and cons of antifungal agents. J Cutan Med Surg. 2004;8(1):25–30. doi:10.1177/120347540400800107
   PubMed Web of Science ®Google Scholar
• Milobratović D, Janković S, Vukičević J, Marinković J, Janković J, Railić Z. Quality of life in patients with toenail onychomycosis. Mycoses. 2013;56(5):543–551. doi:10.1111/myc.12072
   PubMed Web of Science ®Google Scholar
• Elewski BE. The effect of toenail onychomycosis on patient quality of life. Int J Dermatol. 1997;36(10):754–756. doi:10.1046/j.1365-4362.1997.00163.x
   PubMed Web of Science ®Google Scholar
• Szepietowski JC, Reich A, Pacan P, Garlowska E, Baran E. Evaluation of quality of life in patients with toenail onychomycosis by Polish version of an international onychomycosis-specific questionnaire. J Eur Acad Dermatol Venereol. 2007;21(4):491–496. doi:10.1111/j.1468-3083.2006.02004.x
   PubMed Web of Science ®Google Scholar
• Lubeck DP, Patrick DL, McNulty P, Fifer SK, Birnbaum J. Quality of life of persons with onychomycosis. Qual Life Res. 1993;2(5):341–348. doi:10.1007/BF00449429
   PubMed Web of Science ®Google Scholar
• Lubeck DP. Measuring health-related quality of life in onychomycosis. J Am Acad Dermatol. 1998;38(5 Pt 3):S64–68. doi:10.1016/S0190-9622(98)70487-6
   PubMed Web of Science ®Google Scholar
• Whittam LR, Hay RJ. The impact of onychomycosis on quality of life. Clin Exp Dermatol. 1997;22(2):87–89. doi:10.1111/j.1365-2230.1997.tb02626.x
   PubMed Web of Science ®Google Scholar
• Statistics Canada. Utility score norms for each of the chronic conditions examined in the 2013 and 2014 Canadian community health survey, household population aged 12 and older, Canada, 2013 and 2014; 2018. Available from: https://www150.statcan.gc.ca/n1/pub/82-003-x/2018011/article/00001/tbl/tbl03-eng.htm. Accessed February 14, 2024.
   Google Scholar
• Lozano-Ortega G, Mickle A, Gaudet V, Popoff E, Barbeau M. PCR146 preferences for toenail onychomycosis treatments among Canadians with and without diabetes mellitus: a discrete choice experiment. Value Health. 2022;25(12):S419. doi:10.1016/j.jval.2022.09.2081
   PubMed Web of Science ®Google Scholar
• Mickle A, Lozano-Ortega G, Gaudet V, Popoff E, Barbeau M. PCR28 utility values derived from Canadian adults with toenail onychomycosis with and without comorbid diabetes mellitus: a study using the health utilities index®. Value Health. 2022;25(12):S395. doi:10.1016/j.jval.2022.09.1963
   Web of Science ®Google Scholar